Key Findings on Filgotinib Trial for Crohn’s to be Presented at UEG Week

Key Findings on Filgotinib Trial for Crohn’s to be Presented at UEG Week
Galapagos will present endoscopic improvements and other key findings from the FITZROY Phase 2 clinical trial of filgotinib in Crohn's disease, during United European Gastroenterology Week (UEG Week), Oct. 15-19, in Vienna. Lead investigator Dr. Séverine Vermeire will present the abstract titled "Filgotinib, a selective JAK1 inhibitor, induces clinical remission in patients with moderate-to-severe Crohn's disease: final analysis of the Phase 2 FITZROY study" on Oct. 17. The FITZROY trial (NCT02048618) assessed the effectiveness and safety of filgotinib (200 mg once daily) versus placebo in 174 patients with moderate to severe active Crohn’s disease and who were either anti-TNF naive (never treated before) or anti-TNF failures. During UEG Week, Vermeire will show that treatment with filgotinib resulted in clinical remission and also resulted in improvements in endoscopic scores for Crohn's disease. The improvement results were measured by the disease activity measurement tools CGAI and SES-CD, respectively. "The endoscopic improvement and the histopathological benefit are additional strong and relevant indicators contributing to the potential of filgotinib as an oral treatment for Crohn's patients," said Vermeire in a
Subscribe or to access all post and page content.